Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Generic Industry Wants US FDA To Consider Allowing Foreign Reference Products For ANDAs
Jun 29 2019
•
By
Derrick Gingery
Allowing bridging of US and foreign reference standards could lower generic drug development costs, the industry argues. • Source: Shutterstock
More from Generics
More from Biosimilars & Generics